Orchid Pharma, Teva Agree To Settle U.S. Suit Over Parkinson's Drug
This article was originally published in PharmAsia News
Executive Summary
India's Orchid Chemicals & Pharmaceuticals and Teva Pharmaceutical Industries have agreed to drop their suit and counterclaim in a U.S. court over the Israel-based firm's Azilect (rasagiline) for treating Parkinson's disease.